PolyPeptide Forecast, price target & analysts
PolyPeptide Target price 2026 - Analyst rating & recommendation
PolyPeptide Classifications & Recommendation:
PolyPeptide Price Target
| Target Price | CHF34.17 |
| Price | CHF24.45 |
| Potential |
39.75%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target PolyPeptide 2027 .
The average PolyPeptide target price is CHF34.17.
This is
39.75%
register free of charge
CHF46.20
88.96%
register free of charge
CHF29.29
19.80%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend PolyPeptide to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the PolyPeptide stock has an average upside potential 2027 of
39.75%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 314.98 | 376.50 |
| 4.28% | 19.53% | |
| EBITDA Margin | -1.34% | 9.79% |
| 86.51% | 832.46% | |
| Net Margin | -5.77% | -4.66% |
| 63.53% | 19.31% |
9 Analysts have issued a sales forecast PolyPeptide 2025 . The average PolyPeptide sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an PolyPeptide EBITDA forecast 2025. The average PolyPeptide EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 PolyPeptide Analysts have issued a net profit forecast 2025. The average PolyPeptide net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | -0.55 | -0.53 |
| 61.81% | 3.64% | |
| P/E | negative | |
| EV/Sales | 2.19 |
8 Analysts have issued a PolyPeptide forecast for earnings per share. The average PolyPeptide EPS is
This results in the following potential growth metrics and future valuations:
Current PolyPeptide Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JEFFERIES |
Locked
➜
Locked
|
Locked | Nov 19 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 25 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jun 26 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jun 25 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jan 16 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Nov 19 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 25 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Jun 26 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Jun 25 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Jan 16 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
